Brand/Development name: Mesupron, Upamostat
Principal Therapy Area: Cancer
£195 / $340 / €245
WX-671 is an orally-available, second-generation serine protease inhibitor that is designed to target the urokinase plasminogen activator (uPA) system. Wilex' uPA programme is a promising new non-cytotoxic approach in cancer therapy to specifically block tumour metastasis in solid cancers. The uPA system has been shown to play a key role in tumour cell invasion and metastasis, as well as in primary tumour growth, of various solid tumours including breast (BC), ovarian, gastric, colon and pancreatic cancer.
WX-671 is a prodrug of Wilex' intravenous serine protease inhibitor, WX-UK1. The latter reduced the formation of metastases and inhibited primary tumour growth in various preclinical and Phase I trials. Orally-administered WX-671 is converted to WX-UK1 in the body and therefore, has the same mode of action.
final data expected in July 2011.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for email@example.com